Patrick Costello, MD
Ophthalmology · Oneida, NYNPI 1346245156
Payments from drug & device makers
Across 242 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$542
- Sight Sciences, Inc.$472
- Bausch & Lomb Americas Inc.$416
- Beaver-visitec International, Inc.$366
- Glaukos Corporation$248
- plus $2K from 24 others
What the payments were for
- Consulting fees$3506%
- Food & beverage$5,72194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 58 | $1,901 |
| AbbVie(2 entities) | 19 | $542 |
| Sight Sciences, Inc. | 18 | $472 |
| Bausch & Lomb Americas Inc. | 42 | $416 |
| Beaver-visitec International, Inc. | 4 | $366 |
| Glaukos Corporation | 3 | $248 |
| Sun Pharmaceutical Industries Inc. | 9 | $228 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $181 |
| Oyster Point Pharma, Inc. | 9 | $173 |
| Aerie Pharmaceuticals, Inc. | 6 | $172 |
| Amgen(2 entities) | 7 | $170 |
| Biotissue Holdings Inc. | 8 | $168 |
| Mallinckrodt Hospital Products Inc. | 5 | $135 |
| Novartis | 6 | $112 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $97 |
| Tarsus Pharmaceuticals, Inc. | 4 | $95 |
| Carl Zeiss Meditec, Inc. | 1 | $76 |
| Omeros Corporation | 4 | $72 |
| Ocular Therapeutix, Inc. | 4 | $70 |
| Merz Pharmaceuticals, LLC | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Ivantis, Inc | 3 | $55 |
| Harrow Eye, LLC | 3 | $51 |
| Dompe US, Inc. | 2 | $35 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Eyepoint US, Inc. | 1 | $14 |
| Medtronic | 1 | $11 |
| NEW World Medical,inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$483
- ORA$350
- Clareon$270
- Luxor$245
- Constellation$245
- iStent$169
- iStent inject W$169
- KXL System$169
- Photrexa$169
- OMNI$123
- Rocklatan$116
- Rhopressa$116
- DURYSTA$104
How this compares
$6,071 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 48 | $78,040 |
| Prednisolone Acetate | 1,253 | $64,888 |
| Cyclosporine | 67 | $45,711 |
| LumiganBimatoprost | 76 | $43,404 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $30,097 |
| Brinzolamide | 102 | $21,422 |
| CombiganBrimonidine Tartrate/Timolol | 43 | $21,160 |
| RhopressaNetarsudil Mesylate | 45 | $19,833 |
| XiidraLifitegrast | 12 | $19,657 |
| Ketorolac Tromethamine | 1,226 | $19,529 |
| Latanoprost | 1,456 | $19,353 |
| Brimonidine Tartrate | 636 | $13,936 |
| Timolol Maleate | 559 | $13,706 |
| Ofloxacin | 654 | $12,872 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 675 | $11,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $542 | $152,748188 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $172 | $49,931112 claims |
| Bausch & Lomb Americas Inc.Xiidra | $416 | $19,65712 claims |
| AlconSimbrinza | $1,901 | $9,82450 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $97 | $5,20224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Oneida
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.